Highest-materiality recent filing
CFO Eric Hyllengren departs; Marlyn Mathew named principal accounting/financial officer
CFO Eric Hyllengren separated from Zura Bio on April 20, 2026; separation not related to financial/operating results.
Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track
Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
Zura Bio prices $125M public offering of 18.2M shares at $6.25 and 1.8M pre-funded warrants
Offering: 18.2M Class A ordinary shares at $6.25/share, plus 1.8M pre-funded warrants at $6.249 each.
Zura Bio announces CEO resignation and appointment of Sandeep Kulkarni as new CEO
Robert Lisicki resigned as CEO and director effective January 21, 2026, after medical leave since October 2025.
Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital
Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10
CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.
Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027
Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
Zura Bio Q3 net loss $22.9M; cash $188.2M; Phase 2 trials on track for SSc and HS
Net loss of $22.9M ($0.26 per share) vs $8.3M ($0.18) in Q3 2023; G&A up $7.1M on one-time stock comp and warrant exchange.
Zura Bio reports Q2 2024 net loss of $12.7M, cash of $188.4M; plans Phase 2 starts for tibulizumab
Net loss of $12.7M ($0.17/share) vs $44.9M ($1.31/share) in Q2 2023; reduction driven by prior-year acquisition costs.
97.2% of public warrants (6,703,428) and 69% of private warrants (4,080,580) tendered, exchanged for 3,235,184 Class A ordinary shares.
Zura Bio launches warrant exchange offer for 0.30 shares per warrant; expires Aug 8, 2024
Exchange offer for IPO warrants: 0.30 Class A ordinary shares per warrant, up to 3,842,999 shares total.
On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026.
On and effective October 15, 2024, Michael Howell, the Chief Scientific Officer of Zura Bio Limited (the “ Company ”), was separated from the Company.
On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.
Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.
Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.
On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).
On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.
On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023
On June 22, 2023, the Board appointed Parvinder Thiara to fill the vacancy on and serve as a member of the Board, to serve until the next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Chris Cabell, the Company’s Chief Medical Officer and Executive Vice President, will be taking on Dr. Klassen’s duties going forward.
On April 6, 2023, Preston Klassen notified Zura Bio Limited (the “Company”) that he intended to resign as the Company’s President and Chief Operating Officer.
Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.
Max materiality 0.90 · Median 0.50 · Most common event other_material